While specialized centers handle acute CAR-T toxicities like CRS and ICANS, the most life-threatening long-term side effect is infection. This shifts the primary responsibility of care to community hematologists and oncologists, who must proactively manage this risk with patients after they are discharged.
Despite proven efficacy, only 20-30% of eligible patients receive CAR-T therapy. This isn't a medical failure but a systemic one. The most impactful action is to influence policy and economics to improve healthcare funding and access, highlighting that medical innovation alone is insufficient to save lives without the right socioeconomic infrastructure.
For patients who have undergone CAR-T therapy, a common ailment like sinusitis poses a severe risk. Post-nasal drip can lead to life-threatening pneumonia. Effective management requires more than antibiotics; it involves checking immunoglobulin levels, sinus washing, and consulting ENT specialists to correct underlying structural issues.
A cohort in the ZUMA-2 trial for mantle cell lymphoma investigated a four-times lower dose of Brexu-cel, hoping to reduce toxicity. Counterintuitively, the lower dose showed no difference in either safety or efficacy compared to the standard dose. This finding led researchers to abandon the lower-dose approach, challenging the assumption that less is always safer.